{
  "report_rows": [
    {
      "kpi": "Organic Growth Rate (Q4 FY26)",
      "prediction": "BEAT",
      "answer": "pred ~7.8% vs. cons 7.3%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Gross Margin % (Q4 FY26)",
      "prediction": "IN-LINE",
      "answer": "pred ~50.3% vs. cons 50.2%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. Diluted EPS (Q4 FY26)",
      "prediction": "IN-LINE",
      "answer": "pred ~$1.25 vs. cons $1.24",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Revenue (FY2026 - maintain)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$11.21-11.24B vs. cons $11,232M",
      "confidence": "HIGH"
    },
    {
      "kpi": "Adj. EPS (FY2026 - maintain)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$4.86-4.90 vs. cons $4.89",
      "confidence": "HIGH"
    },
    {
      "kpi": "Revenue (FY2027 - initial)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$12.00-12.15B (mid $12.075B) vs. cons $12,069M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EPS (FY2027 - initial)",
      "prediction": "UNCHANGED",
      "answer": "guide ~$5.35-5.45 (mid $5.40) vs. cons $5.42",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Qualitative: UniFirst/FTC tone",
      "prediction": "UNCHANGED",
      "answer": "cautiously constructive; no new timeline acceleration",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 0.5,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 0.8,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE - Archetype B follow-through; FY27 in-line guide gives sell-side little reason to revise; FTC overhang caps upside",
  "day5_confidence": "MEDIUM"
}